^
Association details:
| Biomarker: | MLL2 mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Rubraca (rucaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients
Published date:
10/25/2022
Excerpt:
We found that mutation population of MLL2 appears more sensitive to Rucaparib...our findings also suggest that the DDR gene MLL2 may influence Rucaparib sensitivity in PCa patients.
DOI:
https://doi.org/10.1177/107327482211294
